Altimmune Inc

-0.12 (-1.53%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)306.78M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.11 Million
Adjusted EPS-$0.66
See more estimates
10-Day MA$8.10
50-Day MA$9.57
200-Day MA$11.92
See more pivots

Altimmune Inc Stock, NASDAQ:ALT

910 Clopper Road, Suite 201S, Gaithersburg, Maryland 20878
United States of America
Phone: +1.240.654.1450
Number of Employees: 43


Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on peptide-based therapeutics for obesity and liver diseases. The company is developing pemvidutide (ALT-801), a novel, GLP-1/glucagon dual agonist for the treatment of obesity and non-alcoholic steatohepatitis (NASH), and HepTcell(TM), an immunotherapeutic candidate for patients chronically infected with the hepatitis B virus (HBV). The company was founded in 1997 and is headquartered in Gaithersburg, MD.